Background: Existing studies have yet to investigate the perspectives of patients and professionals concerning relapse prevention programs for patients with remitted anxiety or depressive disorders in primary care. User opinions should be considered when optimizing the use and implementation of interventions.
Objective: This study aimed to evaluate the GET READY relapse prevention programs for patients with remitted anxiety or depressive disorders in general practice.
Methods: Semistructured interviews (N=26) and focus group interviews (N=2) with patients and mental health professionals (MHPs) in the Netherlands were performed. Patients with remitted anxiety or depressive disorders and their MHPs who participated in the GET READY study were interviewed individually. Findings from the interviews were tested in focus group interviews with patients and MHPs. Data were analyzed using thematic analysis.
Results: Participants were positive about the program because it created awareness of relapse risks. Lack of motivation, lack of recognizability, lack of support from the MHP, and symptom severity (too low or too high) appeared to be limiting factors in the use of the program. MHPs play a crucial role in motivating and supporting patients in relapse prevention. The perspectives of patients and MHPs were largely in accordance, although they had different perspectives concerning responsibilities for taking initiative.
Conclusions: The implementation of the GET READY program was challenging. Guidance from MHPs should be offered for relapse prevention programs based on eHealth. Both MHPs and patients should align their expectations concerning responsibilities in advance to ensure optimal usage. Usage of blended relapse prevention programs may be further enhanced by diagnosis-specific programs and easily accessible support from MHPs.
International Registered Report Identifier (irrid): RR2-10.1186/s12888-019-2034-6.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925144 | PMC |
| http://dx.doi.org/10.2196/23200 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study.
Lancet Psychiatry
February 2025
Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Neuroscience Center, University of Helsinki, Helsinki, Finland.
Background: The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different treatment strategies used before and after the first relapse, and their associations with subsequent relapse risk.
Methods: In this population-based cohort study, we enrolled individuals (aged ≤45 years) with first-episode schizophrenia who were hospitalised and subsequently relapsed between 1996 and 2014 from the nationwide Finnish Hospital Discharge Register.
Surgical Helmet Systems do not reduce the incidence of periprosthetic joint infections in elbow arthroplasty. Results from the New Zealand National Joint Registry 2000-2023.
J Shoulder Elbow Surg
January 2025
Department of Orthopaedic Surgery, North Shore Hospital, Takapuna, Auckland, New Zealand; Department of Surgery, University of Auckland, Grafton, Auckland, New Zealand.
Hypothesis And Background: The incidence of prosthetic joint infection (PJI) remains high following elbow arthroplasty procedures. The purpose of this study was to investigate whether Surgical Helmet Systems (SHS) reduce rates of PJI after elbow arthroplasty in a population-based registry study over a consecutive 23-year period. We hypothesized SHS would reduce the incidence of PJI compared with conventional surgical gowns following elbow arthroplasty surgery.
View Article and Find Full Text PDFRespiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
Lancet Infect Dis
January 2025
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Background: New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed.
Methods: We used electronic health records in the Veterans Health Administration to emulate a target trial comparing a single dose of a recombinant stabilised prefusion F protein RSV vaccine versus no vaccination among veterans aged 60 years and older.
Spatiotemporal estimates of anthropogenic NO emissions across China during 2015-2022 using a deep learning model.
J Hazard Mater
January 2025
Key Laboratory of Geographic Information Science of the Ministry of Education, School of Geographic Sciences, East China Normal University, Shanghai 200241, PR China; Institute of Eco-Chongming (IEC), 20 Cuiniao Road, Chenjia Town, Chongming District, Shanghai 202162, PR China. Electronic address:
As one of the significant air pollutants, nitrogen oxides (NO = NO + NO) not only pose a great threat to human health, but also contribute to the formation of secondary pollutants such as ozone and nitrate particles. Due to substantial uncertainties in bottom-up emission inventories, simulated concentrations of air pollutants using GEOS-Chem model often largely biased from those of ground-level observations. To address this issue, we developed a new deep learning model to simulate the inverse process of the GEOS-Chem model.
View Article and Find Full Text PDFPersistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.
PLoS Med
January 2025
Division of Infectious Diseases, Department of Medicine II, Medical Centre and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Background: Self-reported health problems following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are common and often include relatively non-specific complaints such as fatigue, exertional dyspnoea, concentration or memory disturbance and sleep problems. The long-term prognosis of such post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) is unknown, and data finding and correlating organ dysfunction and pathology with self-reported symptoms in patients with non-recovery from PCS is scarce. We wanted to describe clinical characteristics and diagnostic findings among patients with PCS persisting for >1 year and assessed risk factors for PCS persistence versus improvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!